Chronic Hepatitis B
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
Treatment of Chronic Hepatitis B [updated November 2015]
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance [updated February 2018]
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B1 and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients.
Three systematic reviews were commissioned to support the guideline, which were published in November 2015:
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis
Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis
Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis